Examining AnaptysBio's recent Phase 2b data on rosnilimab for the treatment of rheumatoid arthritis (RA)

Scheduled for:Jun 29, 2025 8:00 PM EDT

Call Duration:30 minutes

Desired Expert

Rheumatologist familiar with the data

Interview Goal

This conversation will focus on AnaptysBio investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). We will discuss the global 424-patient Phase 2b trial.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.